Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Colombo M et al. | Influence of Drug Brittleness, Nanomilling Time, and Freeze-Drying on the Crystallinity of Poorly Water-Soluble Drugs and Its Implications for Solubility Enhancement. | 2017 | AAPS PharmSciTech | pmid:28168626 |
Elens L and Haufroid V | Genotype-based tacrolimus dosing guidelines: with or without CYP3A4*22? | 2017 | Pharmacogenomics | pmid:29095105 |
Ma X et al. | Inhibition effect of tacrolimus and platelet-derived growth factor-BB on restenosis after vascular intimal injury. | 2017 | Biomed. Pharmacother. | pmid:28633129 |
Ekman-Joelsson BM et al. | Post-transplant lymphoproliferative disease is associated with early sternotomy and left ventricular hypoplasia during infancy: a population-based retrospective review. | 2017 | Cardiol Young | pmid:28780922 |
Ferreira A et al. | Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus. | 2017 | Am. J. Nephrol. | pmid:28511172 |
Gu K et al. | Atypical pneumonia due to human bocavirus in an immunocompromised patient. | 2017 | CMAJ | pmid:28507089 |
Undre N and Dickinson J | Relative bioavailability of single doses of prolonged-release tacrolimus administered as a suspension, orally or via a nasogastric tube, compared with intact capsules: a phase 1 study in healthy participants. | 2017 | BMJ Open | pmid:28377389 |
Ericzon BG et al. | Pharmacokinetics of prolonged-release tacrolimus versus immediate-release tacrolimus in de novo liver transplantation: A randomized phase III substudy. | 2017 | Clin Transplant | pmid:28295581 |
Xie Y et al. | Delayed Donor Bone Marrow Infusion Induces Liver Transplant Tolerance. | 2017 | Transplantation | pmid:28187014 |
Smolders EJ et al. | Decreased tacrolimus plasma concentrations during HCV therapy: a drug-drug interaction or is there an alternative explanation? | 2017 | Int. J. Antimicrob. Agents | pmid:28185946 |
Sakurai K et al. | Efficacy of combination therapy with tacrolimus and mizoribine for cyclophosphamide-resistant ANCA-associated glomerulonephritis. | 2017 | Int J Rheum Dis | pmid:28205382 |
Nishiya Y et al. | A new efficient method of generating photoaffinity beads for drug target identification. | 2017 | Bioorg. Med. Chem. Lett. | pmid:28108248 |
Wungwattana M and Savic M | Tacrolimus interaction with nafcillin resulting in significant decreases in tacrolimus concentrations: A case report. | 2017 | Transpl Infect Dis | pmid:28067989 |
MartÃn-Fernández M et al. | Effects of Cyclosporine, Tacrolimus, and Rapamycin on Osteoblasts. | 2017 | Transplant. Proc. | pmid:29149986 |
Liberal R et al. | Expert clinical management of autoimmune hepatitis in the real world. | 2017 | Aliment. Pharmacol. Ther. | pmid:28004405 |
Nakamura K et al. | AS2553627, a novel JAK inhibitor, prevents chronic rejection in rat cardiac allografts. | 2017 | Eur. J. Pharmacol. | pmid:27993641 |
Lewis DJ et al. | Oral bexarotene for post-transplant cutaneous T-cell lymphoma. | 2017 | Dermatol Ther | pmid:28748653 |
Gelens MACJ et al. | No evidence for progressive deterioration in stimulated insulin secretion in renal transplant recipients after 12years tacrolimus exposure. | 2017 | J. Diabetes Complicat. | pmid:28720321 |
Chen P et al. | Dynamic effects of CYP3A5 polymorphism on dose requirement and trough concentration of tacrolimus in renal transplant recipients. | 2017 | J Clin Pharm Ther | pmid:27885697 |
Zhang W et al. | Isoglycyrrhizinate Magnesium Enhances Hepatoprotective Effect of FK506 on Ischemia-Reperfusion Injury Through HMGB1 Inhibition in a Rat Model of Liver Transplantation. | 2017 | Transplantation | pmid:28885495 |